Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...

Presented a poster highlighting the use of the Company's Magellan™ drug discovery platform to identify allosteric inhibitors ...

Huntington's disease is a rare genetic, autosomal dominant, neurodegenerative disease, caused by CAG repeat expansions in the ...

elegans and mammalian neuronal cultures (Fonte et al, 2011). We propose that a primary mechanism of Abeta toxicity is the formation of membrane-damaging oligomers, which is blocked by the G37L ...

However, the precise mechanisms governing binding specificity and the formation of preferential interactions between neuronal ...

“So it is providing that sort of link between inflammation in the brain, the death of neurons and MS progression.” Multiple sclerosis is a progressive neurological disease that affects 33,000 ...